Skip to main content
Home > The Daily Extra > Top Story

Chronological Index of : Top Story

 Current Issue
  • TOP STORY: Obesity play Zafgen files for IPO

    Zafgen Inc. (Cambridge, Mass.) filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by Leerink; Cowen; Canaccord; and JMP Securities. Zafgen is developing beloranib, a subcutaneous formulation of a …

    Published on 4/18/2014
  • TOP STORY: FDA approves Ragwitek

    FDA approved a BLA from Merck & Co. Inc. (NYSE:MRK) for Ragwitek, a ragweed sublingual allergy immunotherapy tablet (AIT), to treat ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, in patients …

    Published on 4/17/2014
  • TOP STORY: Epirus raises $36 million, to reverse-merge

    Biosimilar company Epirus Biopharmaceuticals Inc. (Boston, Mass.) raised $36 million in a series B round and said it will reverse-merge with Zalicus Inc. (NASDAQ:ZLCS) in an all-stock deal. The combined, publicly traded…

    Published on 4/16/2014
  • TOP STORY: PanOptica secures $45 million in series B

    Ophthalmology play PanOptica Inc. (Mount Arlington, N.J.) secured $45 million in a tranched series B round co-led by new investor Novo Ventures and existing investor Third Rock Ventures. Existing investor SV Life …

    Published on 4/15/2014
  • TOP STORY: Cytos to wind down operations

    Cytos Biotechnology AG (SIX:CYTN) fell CHF2.72 (95%) to CHF0.15 on Monday after CYT003 -- its only product -- failed in a Phase IIb allergic asthma trial and the company said it is evaluating options to wind down …

    Published on 4/14/2014
  • TOP STORY: Obama nominates Burwell as HHS secretary

    President Obama sent the nomination of Sylvia Matthews Burwell as HHS secretary to the Senate for confirmation. Burwell would replace Kathleen Sebelius, who is resigning. Burwell has served as director of the U.S. …

    Published on 4/11/2014
  • TOP STORY: Biotech, broader markets fall

    The BioCentury 100 Index shed 282.93 points, or 5.6%, to 4,806.06 on Thursday amid a slide in the broader markets. Other healthcare indices were also down on the day. The NASDAQ Biotechnology index and the NYSE Arca …

    Published on 4/10/2014
  • TOP STORY: Moch resigns as Chimerix president, CEO

    Infectious disease company Chimerix Inc. (NASDAQ:CMRX) said Kenneth Moch resigned as president and CEO to pursue other interests. M. Michelle Berrey will replace Moch as president and CEO and will continue to serve as …

    Published on 4/9/2014
  • TOP STORY: Express Scripts to pressure Gilead on Sovaldi pricing

    Express Scripts Holding Co. (NASDAQ:ESRX) said it will ask plan sponsors to "stand side-by-side" with the pharmacy benefit manager to encourage Gilead Sciences Inc. (NASDAQ:GILD) to provide HCV drug Sovaldi sofosbuvir …

    Published on 4/8/2014
  • TOP STORY: Mallinckrodt to acquire Questcor

    Specialty pharma Mallinckrodt plc (NYSE:MNK) will acquire Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) in a cash and stock deal that the companies said values Questcor at about $86.10 per share, or about $5.6 billion. …

    Published on 4/7/2014
  • TOP STORY: Meda up after rejecting Mylan bid

    Specialty pharma company Meda AB (SSE:MEDAA) jumped SEK13.70 (14%) to SEK110.60 on Friday after disclosing that its board rejected a proposal from generics company Mylan Inc. (NASDAQ:MYL) to "combine the two businesses.…

    Published on 4/4/2014
  • TOP STORY: Corium raises $52 million in IPO

    Drug delivery company Corium International Inc. (NASDAQ:CORI) raised $52 million through the sale of a bumped up number of shares below its proposed price range in an IPO on NASDAQ. The company sold 6.5 million shares …

    Published on 4/3/2014
  • TOP STORY: FDA approves Stallergenes' Oralair

    FDA approved Oralair from Stallergenes S.A. (Euronext:GENP) to treat grass pollen-induced allergic rhinitis with or without conjunctivitis in people aged 10-65 years. The U.S. approval triggers a $10 million milestone …

    Published on 4/2/2014
  • TOP STORY: Celgene, Forma in second deal

    Celgene Corp. (NASDAQ:CELG) and Forma Therapeutics Holdings LLC (Watertown, Mass.) partnered to discover and develop compounds targeting undisclosed protein families across a range of therapeutic areas. Celgene paid …

    Published on 4/1/2014
  • TOP STORY: Amgen gains on evolocumab update

    Amgen Inc. (NASDAQ:AMGN) gained $2.79 to $123.34 on Monday after the company for the first time provided detailed data from five Phase III trials of subcutaneous evolocumab (AMG 145). The company previously said …

    Published on 3/31/2014
  • TOP STORY: Baxter to split

    Baxter International Inc. (NYSE:BAX) said it will split its medical products and biopharmaceuticals businesses into two public companies. The pharma said the businesses operate in distinct markets and have different "…

    Published on 3/27/2014
  • TOP STORY: NICE proposes changes to assessment methodology

    The U.K.'s NICE is seeking input on proposed changes to its health technology assessment methodology that the agency said would more explicitly take into account the burden of a person's illness and the wider impact of …

    Published on 3/26/2014
  • TOP STORY: Transgene raises EUR 65.5 million

    Transgene S.A. (Euronext:TNG) raised EUR 65.5 million ($90.4 million) in a combined rights issue and private placement. The company raised EUR 45.5 million ($62.8 million) through the sale of 4.6 million shares in the …

    Published on 3/25/2014
  • TOP STORY: More red for biotech

    The BioCentury 100 Index fell 179.39 points, or 3.3%, to 5,233.33 on Monday. Coupled with Friday's hosing, the index is off 7.7% in the last two trading days. Monday's big decliners included Biogen Idec Inc. (NASDAQ:…

    Published on 3/24/2014
  • TOP STORY: Biotech falls, broader markets flat

    The BioCentury 100 Index fell 257.11 points, or 4.5%, to 5,412.73 on Friday, while the broader markets remained relatively even. The day's big decliners included Biogen Idec Inc. (NASDAQ:BIIB), which fell $28.51 (8%) to…

    Published on 3/21/2014
  • TOP STORY: Anemia play Akebia jumps in trading debut

    Akebia Therapeutics Inc. (NASDAQ:AKBA) raised $100 million in an IPO through the sale of a bumped-up number of shares at the high end of its proposed price range. The company sold 5.9 million shares at $17, valuing …

    Published on 3/20/2014
  • TOP STORY: Horizon Pharma to acquire Vidara

    Specialty pharma Horizon Pharma Inc. (NASDAQ:HZNP) will acquire Vidara Therapeutics International Ltd. (Dublin, Ireland) through a reverse merger in a cash and stock deal that Horizon said values Vidara at about $660 …

    Published on 3/19/2014
  • TOP STORY: NVS said to be in talks for Gamida takeout

    Novartis AG (NYSE:NVS; SIX:NOVN) and Gamida Cell Ltd. (Jerusalem, Israel) both declined to comment on rumors in the Israeli media that Novartis is in "advanced talks" to acquire the Israeli biotech for up to $600 …

    Published on 3/18/2014
  • TOP STORY: Five Prime gains on BMS discovery deal

    Five Prime Therapeutics Inc. (NASDAQ:FPRX) jumped $4.24 (23%) to $22.99 on Monday after partnering with Bristol-Myers Squibb Co. (NYSE:BMY) to identify targets in two undisclosed immune checkpoint pathways. Five Prime…

    Published on 3/17/2014
  • TOP STORY: InterMune raises $245.6 million in follow-on

    InterMune Inc. (NASDAQ:ITMN) raised $245.6 million through the sale of 7.5 million shares at $32.75 in the largest follow-on so far this year topping the $211 million that Synageva BioPharma Corp. (NASDAQ:GEVA) raised…

    Published on 3/14/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993